Artificial pancreas with two hormones could ease diabetes management

NCT ID NCT05669547

Completed Disease control Sponsor: UMC Utrecht Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a fully automated system that delivers both insulin and glucagon to manage blood sugar in adults with type 1 diabetes. Over 12 months, 243 participants used either the dual-hormone device or their usual care. The goal was to see if the system helps keep blood sugar in a healthy range more consistently.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dual-hormone fully closed loop system (Inreda AP device delivering insulin and glucagon)
What this could lead to: If successful, this could offer a more automated way to manage type 1 diabetes, reducing the daily burden of constant monitoring and manual insulin dosing.
What could go wrong: This is a completed trial, but results are not yet widely known. The system is complex and may have technical issues or side effects like low blood sugar. It is not a cure and requires ongoing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES DIABETES MELLITUS, TYPE 1 DIABETES TYPE1

Contacts and locations

Locations

Amsterdam UMC, AMC

Amsterdam, Netherlands
Amsterdam UMC, VUmc

Amsterdam, Netherlands
Catharina Ziekenhuis

Eindhoven, Netherlands
Gelre Ziekenhuis

Apeldoorn, Netherlands
Isala Klinieken

Zwolle, Netherlands
LUMC

Leiden, Netherlands
Martini Ziekenhuis

Groningen, Netherlands
Meander MC

Amersfoort, Netherlands
OLVG

Amsterdam, Netherlands
Rijnstate

Arnhem, Netherlands
St. Antonius

Nieuwegein, Netherlands
Tergooi Ziekenhuis

Hilversum, Netherlands
UMC Groningen

Groningen, Netherlands
UMC Utrecht

Utrecht, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.